LOUIS SILVERSTEIN, M.D.

Transitional care management services for problem of high complexity

Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit

Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use

New patient office or other outpatient visit, 60-74 minutes

Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment

New patient office or other outpatient visit, 45-59 minutes

Established patient office or other outpatient visit, 40-54 minutes

Established patient office or other outpatient visit, 30-39 minutes

Sarscov2 vac 50 mcg/0.5ml im

Established patient office or other outpatient visit, 20-29 minutes

Removal of impacted ear wax

Established patient office or other outpatient visit, 10-19 minutes

Influenza vaccine split virus, preservative free

Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza

Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and

Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report

Detection test by immunoassay with direct visual observation for streptococcus, group a (strep)

Management using the results of remote vital sign monitoring per calendar month, first 20 minutes

Stool analysis for blood, by fecal hemoglobin determination by immunoassay

Smoking and tobacco use intensive counseling, 4-10 minutes

Administration of influenza virus vaccine

Annual alcohol misuse screening, 5 to 15 minutes

Administration of pneumococcal vaccine

Annual depression screening, 5 to 15 minutes

Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes

Adm sarscv2 bvl 50mcg/.5ml a

Admn sarscov2 vacc 1 dose

Injection of drug or substance under skin or into muscle

Injection, denosumab, 1 mg

Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment

Urinalysis, manual test

Hemoglobin a1c level

Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg

Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg

Sarscov2 vac bvl 50mcg/0.5ml